$3.11 Billion is the total value of Tekla Capital Management LLC's 171 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMN | New | AMN Healthcare Services, Inc. | $7,487,000 | – | 61,201 | +100.0% | 0.24% | – |
| CYTK | New | Cytokinetics, Inc. | $4,233,000 | – | 92,871 | +100.0% | 0.14% | – |
| ACAD | New | ACADIA Pharmaceuticals Inc. | $1,686,000 | – | 72,225 | +100.0% | 0.05% | – |
| New | Pyxis Oncology, Inc. | $1,481,000 | – | 135,000 | +100.0% | 0.05% | – | |
| New | Astellas Pharma Inc. | $1,445,000 | – | 88,837 | +100.0% | 0.05% | – | |
| DSGN | New | Design Therapeutics, Inc. | $1,399,000 | – | 65,351 | +100.0% | 0.04% | – |
| MRUS | New | Merus N.V. | $1,331,000 | – | 41,857 | +100.0% | 0.04% | – |
| CERE | New | Cerevel Therapeutics Holdings, Inc. | $1,329,000 | – | 41,003 | +100.0% | 0.04% | – |
| New | Theseus Pharmaceuticals, Inc. | $1,268,000 | – | 100,000 | +100.0% | 0.04% | – | |
| BEAM | New | Beam Therapeutics Inc. | $1,260,000 | – | 15,817 | +100.0% | 0.04% | – |
| ACET | New | Adicet Bio, Inc. | $1,108,000 | – | 63,329 | +100.0% | 0.04% | – |
| EWTX | New | Edgewise Therapeutics, Inc. | $925,000 | – | 60,550 | +100.0% | 0.03% | – |
| KOD | New | Kodiak Sciences Inc. | $723,000 | – | 8,530 | +100.0% | 0.02% | – |
| RPTX | New | Repare Therapeutics Inc. | $615,000 | – | 29,150 | +100.0% | 0.02% | – |
| IDYA | New | IDEAYA Biosciences, Inc. | $484,000 | – | 20,454 | +100.0% | 0.02% | – |
| New | Nexgel | $11,000 | – | 4,243 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.